Stock info Coloplast | Filter  Basic-Info

Coloplast

Coloplast's head office is based in Humlebaek. The company mostly operates in the pharmaceutical sector. Lars Rasmussen is the company' CEO. Coloplast' CFO is Anders LonningSkovgaard. The past 10 years the (international) industry gained at around 75 percent. Over the past 5 years the sector is 147 percent higher.

The past year was a profitable year Coloplast investors

Over the past year the company' stock lost around 12 percent. Over the period 2011-2016 the stock rose a massive 194,13 percent. Coloplast's revenues between 2011 and 2015 were very volatile and moved between 2,65 billion euros and 3,34 billion euros. The net results between 2011 and 2015 were far from constant and fluctuated between 1,82 billion euros and 899 million euros.

The Danish company paid out dividends in the past 5 years. Coloplast's dividend return over the period 2011 - 2015 was around 40,8 percent per year.

At the end of 2015 Coloplast employed at around 9070 thousand people.

Coloplast financed with a quite low debt position

At the end of 2015 the Danish company had a balance sheet of 10,82 billion euros. 6,11 billion euros (56,49 percent of the total balance sheet) was financed by debt. At the end of 2015 the pharmaceutical company's stock was traded with a price/earnings-ratio 36. So the stock' value was 36 times the 2015' earnings per share. Based on the classical stock valuation theories the Danish stock can be seen as a value stock.

The pharmaceutical company's market capitalization (the number of shares outstanding times the market value) equaled around 115,21 billion euros. At the end of 2015 the Danish company had around 211 million stocks listed on the stock exchange(s).

At this page you find all Coloplast's financial reports. More information about Coloplast can be found it's website. .